Novo Nordisk Makes FORTUNE's List Of '100 Best Companies To Work For' For Third Straight Year
PRINCETON, N.J., Jan. 20, 2011 /PRNewswire/ -- For a third consecutive year, Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's prestigious "100 Best Companies to Work For" list for 2011. Novo Nordisk is ranked 47th in the overall list and is only one of three pharmaceutical/biotechnology companies so honored.
"We are extremely honored to be recognized by FORTUNE as one of the '100 Best Companies to Work For'," said Jerzy Gruhn, president of Novo Nordisk Inc. "Everyone in Novo Nordisk has a personal interest in defeating diabetes and supporting patients with hemophilia and other serious conditions. We are so glad to see these efforts noticed for three years in a row."
To pick the "100 Best Companies to Work For," FORTUNE partners with the Great Place to Work Institute to conduct the most extensive employee survey in corporate America. Three hundred eleven companies participated in this year's survey. Two-thirds of a company's score is based on the results of the Institute's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management's credibility, job satisfaction, and camaraderie. The other third of the scoring is based on the company's responses to the Institute's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, internal communications, training, recognition programs and diversity efforts."At Novo Nordisk, we're all active stewards of our corporate culture. It's that engagement that allows us to develop and provide medicines of value for people with diabetes and hemophilia," said Jeff Frazier, Vice President of Human Resources. "I appreciate that our efforts to reward our employees for all their great work is recognized by FORTUNE and others in our industry." About Novo Nordisk Novo Nordisk is a healthcare company with an 87-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV